Drug Combination Details
| General Information of the Combination (ID: C74006) | |||||
|---|---|---|---|---|---|
| Name | Oridonin NP Info | + | Cetuximab Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Laryngeal cancer
[ICD-11: 2C23]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BECN1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PRKAA2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | PRKAA2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HEp-2 | CVCL_1906 | Laryngeal carcinoma | Homo sapiens | ||
| Tu 212 | CVCL_4915 | Head and neck squamous cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Autophagy might be strongly associated with the antitumor efficacy of ORI/Cet, which may be beneficial to the clinical application of ORI/Cet in LSCC treatment ORI/Cet in LSCC treatment. | |||||
